Application of Nanotechnology in Drug and Gene Delivery

Authors

  • Vijay Sagar Madamsetty Department of Biochemistry and Molecular Biology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL-32224, United States Author

Abstract

Despite recent advances in clinical research, the major problem faced by clinics is the lack of effective therapeutic approaches to treat 
various diseases. Most of the current therapeutic agents are waternsoluble leading to poor bioavailability, the least effect at the disease site, and severe therapy-associated side effects. Scientists from diverse parts of the globe are working hard in day and night to resolve these issues and improve the therapeutic benefits of the treatment. Recent years have witnessed unexpected growth in research in the area of nanotechnology [1]. The application of nanotechnology in drug and gene delivery has become attractive over the past few decades in health care and other fields [2]. There is increasing confidence that nanotechnology applied to medicine will significantly advance cancer diagnosis, treatment, and prevention. The growing interest in nanotechnology’s future medical applications leads to the emergence of a new field called nanomedicine, aiming to maximize the therapeutic index, vastly expand the human lifespan, and minimize undesirable side effects [3]. However, to realize that potential, it needs to overcome several major hurdles, including improving circulation stability and disease site targeting efficacy. 

References

Gharpure, KM, Wu SY, Li C. “ Lopez-Berestein, G.; Sood, A. K. Nanotechnology: Future of Oncotherapy”. Clin Cancer Res 21 (2015): 3121-3130.

Poon W, Kingston BR, Ouyang B, Ngo W, Chan WCW. “A framework for designing delivery systems”. Nature Nanotechnology 15 (2020): 819-829.

Van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. “Smart cancer nanomedicine”. Nature Nanotechnology 14 (2019) 1007-1017. DOI: 10.47755/J Nanotech Nanomed Res.2020.1.002

Zhang Y, Li M, Gao X, Chen Y, Liu T. “Nanotechnology in cancer diagnosis: progress, challenges and opportunities”. J Hematology Oncology 12 (2019): 137.

Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, et al. “Nanocarriers as an emerging platform for cancer therapy”. Nature Nanotechnology 2 (2007): 751-760.

Sun D, Zhou S, Gao W. “What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right”. ACS Nano 14 (2020): 12281-12290.

Anselmo AC, Mitragotri S. “Nanoparticles in the clinic: An update”. Bioeng Transl Med 4 (2019): e10143-e10143.

Khorasani AA, Weaver JL, Salvador-Morales C. “Closing the gap: accelerating the translational process in nanomedicine by proposing standardized characterization techniques”. Int J Nanomedicine, 9(2014): 5729-5751. DOI: 10.47755/J Nanotech Nanomed Res.2020.1.002 Vijay Sagar Madamsetty et al., (2020) 1: 001-002

Foulkes R, Man E, Thind J, Yeung S, Joy A, et al. “The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives”. Biomaterials Science 8 (2020): 4653-4664.

Jain D, Raturi R, Jain V, Bansal P, Singh R. “Recent technologies in pulsatile drug delivery systems”. Biomatter 1 (2011):57-65.

Downloads

Published

2020-12-07